Page 102 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Table 8. Monitoring criteria in protocols of observational management strategies with palliative intent in chronological order of starting
enrollment year

Center, Monitoring schedule PSA Gleason # biopsy Imaging Behavioral Additional Triggers for interventions
Country score cores /% indication laboratory
[Pubmed ID] cores tests
Enrollment
years
Howard Every 3 mo for the first 5 √ – – Annual bone – PAP Signs and/or symptoms of
University yr, every 4-6 mo (after scan; CT of the disease activity.
College of thereafter. Assessment 1985) pelvis was used
Medicine, included DRE, PAP and infrequently
US 138 since 1985 a PSA was
[1600492] done.

1967-1989
Orebro Medical Every 6-12 mo clinical √ (in – – Bone scan – PAP Patients were treated
Center, exam, PAP, and bone the last hormonally if disease
Sweden 139 scans. PSA only few yr) progressed for they had
[7933233] performed in the last few symptoms of progression.
yr
1977-1984
Northern Every 3 to 6 mo for the – – – Bone scan every – PAP Treatment was offered if
Stockholm, first 2 yr and every 6 to 12 to 18 mo clinical progression with
Sweden 140 12 mo thereafter with symptoms
[17467883] DRE and PAP; annual
rebiopsies during the first
1978-1982 4 yr
Freeman NR (“Disease – – – 6-monthly bone – Acid and No treatment until
hospital, UK 141 progression was scans (after alkaline symptomatic progression.
[3191340] monitored”) 1983) phosphatase

1978-1985
Western Every 3 mo – – – Chest X-rays, – √ Progression of disease
General skeletal X-rays (i.e., development of
Hospital, UK 142 and bone scans metastases (M1) or
[8343901] every 6 mo elevation of PAP to > 2 u/l)
and/or development of
1978-1990 symptoms.

53